Germany · Delayed Price · Currency is EUR Cocrystal Pharma Statistics
Total Valuation
FRA:8CC has a market cap or net worth of EUR 12.60 million. The enterprise value is 7.30 million.
| Market Cap | 12.60M |
| Enterprise Value | 7.30M |
Important Dates
The last earnings date was Friday, November 21, 2025.
| Earnings Date | Nov 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 13.78M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.91% |
| Shares Change (QoQ) | +8.03% |
| Owned by Insiders (%) | 32.34% |
| Owned by Institutions (%) | 4.82% |
| Float | 9.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.93 |
| P/TBV Ratio | 1.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.89 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.89 |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.78 |
| Quick Ratio | 5.42 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.16 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -94.94% and return on invested capital (ROIC) is -51.24%.
| Return on Equity (ROE) | -94.94% |
| Return on Assets (ROA) | -45.77% |
| Return on Invested Capital (ROIC) | -51.24% |
| Return on Capital Employed (ROCE) | -109.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -749,327 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.44% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -56.44% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 49.58 |
| Average Volume (20 Days) | 600 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | -4.66M |
| Operating Income | -8.33M |
| Pretax Income | -8.24M |
| Net Income | -8.24M |
| EBITDA | -8.25M |
| EBIT | -8.33M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
The company has 6.59 million in cash and 1.35 million in debt, giving a net cash position of 5.24 million.
| Cash & Cash Equivalents | 6.59M |
| Total Debt | 1.35M |
| Net Cash | 5.24M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.54M |
| Book Value Per Share | 0.50 |
| Working Capital | 6.19M |
Cash Flow
In the last 12 months, operating cash flow was -8.20 million and capital expenditures -10,228, giving a free cash flow of -8.21 million.
| Operating Cash Flow | -8.20M |
| Capital Expenditures | -10,228 |
| Free Cash Flow | -8.21M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:8CC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.91% |
| Shareholder Yield | -1.91% |
| Earnings Yield | -65.41% |
| FCF Yield | -65.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |